Literature DB >> 29634605

Distribution of Adrenergic Receptor Subtypes and Responses to Topical 0.5% Apraclonidine in Patients With Blepharoptosis.

Seong Jun Park1, Sun Young Jang2, Ji Sun Baek3, Susie Chin4, Jae Woo Jang3.   

Abstract

PURPOSE: To determine the relationship between the distribution of adrenergic receptors in the human eyelid and the eyelid elevation after topically instilling 0.5% apraclonidine in blepharoptosis patients.
METHODS: A total of 26 blepharoptotic patients (30 eyelids) were included in the experimental study. Marginal reflex distance 1 was measured before and after topical instillation of 0.5% apraclonidine. Eyelids were divided into 2 groups according to the responses to topical 0.5% apraclonidine. Patients who positively responded to apraclonidine were classified as group A and those that negatively responded to it were classified as group B. Müller's muscle was obtained during the blepharoptotic surgery, followed by immunohistochemical staining and scoring. This study was approved by the Institutional Review Board of Kim's Eye Hospital and the study protocol adhered to the tenets of the Declaration of Helsinki.
RESULTS: α-1D staining intensity was significantly higher in group A than in B (p < 0.001) and α-2C and β-1 staining intensities were significantly higher in group B than in A (p < 0.001 and p < 0.05, respectively). The difference in β-2 staining intensity between groups A and B was not statistically significant.
CONCLUSIONS: α-1D adrenoceptor was predominant in patients showing a positive response to topical 0.5% apraclonidine. Because apraclonidine has an α-1 agonistic effect, α-1D adrenoceptor may contribute to apraclonidine's elevating effect in patients with blepharoptosis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29634605     DOI: 10.1097/IOP.0000000000001095

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  3 in total

Review 1.  A review of acquired blepharoptosis: prevalence, diagnosis, and current treatment options.

Authors:  Jason Bacharach; Wendy W Lee; Andrew R Harrison; Thomas F Freddo
Journal:  Eye (Lond)       Date:  2021-04-29       Impact factor: 3.775

2.  Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials.

Authors:  David L Wirta; Michael S Korenfeld; Shane Foster; Robert Smyth-Medina; Jason Bacharach; Shane R Kannarr; Mark J Jaros; Charles B Slonim
Journal:  Clin Ophthalmol       Date:  2021-10-08

3.  Palpebral Fissure Response to Phenylephrine Indicates Autonomic Dysfunction in Patients With Type 1 Diabetes and Polyneuropathy.

Authors:  Thomas Arendt Nielsen; Carl Uggerhøj Andersen; Henrik Vorum; Sam Riahi; Rok Sega; Asbjørn Mohr Drewes; Jesper Karmisholt; Poul Erik Jakobsen; Birgitte Brock; Christina Brock
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-08-02       Impact factor: 4.925

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.